Confluence Wealth Services’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,484
Closed -$279K 478
2026
Q1
$279K Sell
3,484
-127
-4% -$10.5K 0.01% 328
2025
Q4
$308K Sell
3,611
-105
-3% -$8.62K 0.01% 316
2025
Q3
$289K Sell
3,716
-160
-4% -$12.5K 0.01% 321
2025
Q2
$303K Buy
3,876
+25
+0.6% +$1.86K 0.02% 306
2025
Q1
$271K Sell
3,851
-1,314
-25% -$94K 0.02% 300
2024
Q4
$356K Buy
5,165
+1,243
+32% +$87K 0.02% 258
2024
Q3
$259K Sell
3,922
-1,808
-32% -$131K 0.02% 301
2024
Q2
$529K Buy
5,730
+376
+7% +$33.3K 0.04% 220
2024
Q1
$512K Buy
5,354
+1,084
+25% +$91.1K 0.05% 206
2023
Q4
$326K Sell
4,270
-311
-7% -$21.6K 0.04% 229
2023
Q3
$317K Buy
4,581
+342
+8% +$27.5K 0.06% 207
2023
Q2
$400K Buy
4,239
+12
+0.3% +$1.04K 0.08% 181
2023
Q1
$350K Buy
4,227
+197
+5% +$15.5K 0.08% 176
2022
Q4
$301K Buy
4,030
+225
+6% +$17.3K 0.08% 187
2022
Q3
$314K Sell
3,805
-128
-3% -$12.3K 0.13% 174
2022
Q2
$408K Buy
3,933
+231
+6% +$23.9K 0.18% 173
2022
Q1
$435K Buy
3,702
+5
+0.1% +$561 0.16% 155
2021
Q4
$478K Buy
+3,697
New +$431K 0.15% 145

Other funds holding EW

Confluence Wealth Services's EW Position: Q2 2026 in Review

Confluence Wealth Services sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 3,484 shares — an estimated $279K sold.

Confluence Wealth Services first reported a position in EW in Q4 2021 and held it in 18 quarters. The position peaked at $529K in Q2 2024. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Confluence Wealth Services reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Confluence Wealth Services sold 3,484 Edwards Lifesciences shares in Q2 2026, an estimated $279K.
  • Confluence Wealth Services first reported a position in Edwards Lifesciences in Q4 2021 and held it in 18 quarters.
  • Confluence Wealth Services's Edwards Lifesciences position peaked at $529K in Q2 2024.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Confluence Wealth Services's 13F filing for Q2 2026, filed 22 Jul 2026.